InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists
28 nov. 2022 08h00 HE
|
InspireMD Inc.
TEL AVIV, Israel, Nov. 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced a...
InspireMD Announces Multiple Presentations Featuring CGuard EPS and its Novel MicroNet Mesh Covering at the 2022 VEITH Symposium
15 nov. 2022 16h05 HE
|
InspireMD Inc.
TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the...
InspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference
13 sept. 2022 16h05 HE
|
InspireMD Inc.
TEL AVIV, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the...
InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update
09 août 2022 07h00 HE
|
InspireMD Inc.
- Generated 47.8% growth in CGuard™ revenue year-over-year - - Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission - -...
InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update
02 août 2022 08h00 HE
|
InspireMD Inc.
- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, Aug. 02, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent...
InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor
14 juil. 2022 08h00 HE
|
InspireMD Inc.
TEL AVIV, Israel, July 14, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced the...
InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022
09 juin 2022 08h00 HE
|
InspireMD Inc.
TEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today provided the...
InspireMD’s CGuard™ Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmission at LINC 2022
02 juin 2022 08h00 HE
|
InspireMD Inc.
TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the...
InspireMD Reports First Quarter 2022 Financial Results and Business Update
10 mai 2022 07h30 HE
|
InspireMD Inc.
- 20% growth in CGuard™ revenue Year-over-Year - - C-Guardian FDA IDE Trial Completes First European Enrollment - - Held Key Opinion Leader (KOL) Webinar on Carotid...
InspireMD to Report First Quarter 2022 Financial Results on May 10, 2022 and Provide Corporate Business Update
28 avr. 2022 07h30 HE
|
InspireMD Inc.
TEL AVIV, Israel, April 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...